Cargando…

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

Type 2 diabetes mellitus (T2DM) is highly prevalent in the general population and especially in patients with heart failure (HF). It is not only a risk factor for incident HF, but is also associated with worse outcomes in prevalent HF. Therefore, antihyperglycaemic management in patients at risk of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savarese, Gianluigi, Schrage, Benedikt, Cosentino, Francesco, Lund, Lars H., Rosano, Giuseppe M.C., Seferovic, Petar, Butler, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755024/ https://www.ncbi.nlm.nih.gov/pubmed/32909376 http://dx.doi.org/10.1002/ehf2.12937

Ejemplares similares

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure
por: Lindberg, Felix, et al.
Publicado: (2022)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Physiological monitoring in the complex multi-morbid heart failure patient - Introduction
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
por: Aktaa, Suleman, et al.
Publicado: (2022)

Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom
por: Seferovic, Petar M., et al.
Publicado: (2021)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
por: Kapelios, Chris J, et al.
Publicado: (2023)

Global Public Health Burden of Heart Failure: An Updated Review
por: Shahim, Bahira, et al.
Publicado: (2023)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
por: Kapelios, Chris J, et al.
Publicado: (2023)

Heart Failure and Importance of Collaboration of Professional Organizations: The Role of the Heart Failure Association of the European Society of Cardiology and Its Committee on National Heart Failure Societies
por: Çavuşoğlu, Yüksel, et al.
Publicado: (2015)

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
por: Ceriello, Antonio, et al.
Publicado: (2021)

Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis
por: Salah, Husam M., et al.
Publicado: (2023)

Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry
por: Kapłon‐Cieślicka, Agnieszka, et al.
Publicado: (2020)

Introduction to the special issue entitled ‘Heart failure management of the elderly patient: focus on frailty, sarcopenia, cachexia, and dementia’
por: Seferović, Petar M
Publicado: (2019)

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
por: Niezen, Sebastian, et al.
Publicado: (2019)

Heart failure in dilated non-ischaemic cardiomyopathy
por: Seferović, Petar M, et al.
Publicado: (2019)

Physiological monitoring of the complex multimorbid heart failure patient – diabetes and monitoring glucose control
por: Seferović, Petar M, et al.
Publicado: (2019)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Importance of Adding Quality of Life to Years of Life in Patients With Heart Failure
por: Cannata, Antonio, et al.
Publicado: (2023)

‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor
por: Abdin, Amr, et al.
Publicado: (2021)

Impact analysis of heart failure across European countries: an ESC‐HFA position paper
por: Rosano, Giuseppe M.C., et al.
Publicado: (2022)

Paederia foetida Linn. leaf extract: an antihyperlipidemic, antihyperglycaemic and antioxidant activity
por: Kumar, Vikas, et al.
Publicado: (2014)

Aqueous extract of Tamarindus indica fruit pulp exhibits antihyperglycaemic activity
por: Krishna, Rajesh Nivesh, et al.
Publicado: (2020)

New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology
por: Jaarsma, Tiny, et al.
Publicado: (2020)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2019)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2hm8gmkb9fhr0gcknhbtlno32g